Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PFIZER INCPFE · Entity 2863 | Executive Vice President | August 13, 2018 | August 14, 2018 |
| Quanterix CorpQTRX · Entity 6649 | Director | May 14, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PFIZER INC
Report date August 13, 2018 · Filed August 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,672 |
Reported balance
After 2018-08-13 transaction · row 1
1 source rowRow 1 · 2018-08-13 · Sale · Disposed 10,214 · Balance 72,672 |
| Common StockSEC Table I · non-derivative | IndirectBy Rule 16b-3 Plan | 5,529 |
Reported balance
Holding disclosure · report date 2018-08-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,529 |
Quanterix Corp
Report date May 14, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,738 |
Reported balance
After 2024-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-14 · Sale · Disposed 1,500 · Balance 13,738 F1: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023. F2: Includes 2,947 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023.
F2: Includes 2,947 restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Karuna Therapeutics, Inc.
Report date March 18, 2024 · Filed March 18, 2024
Section 16 reporting ended · disclosed 2024-03-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 1
1 source rowRow 1 · 2024-03-18 · Disposition to issuer · Disposed 990 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.86 · Expires 2030-08-11 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-18 · Disposition to issuer · Disposed 13,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.01 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-18 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.96 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-03-18 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F4: These Options are fully vested. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.70 · Expires 2033-06-19 | Direct | 0 |
Reported balance
After 2024-03-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-03-18 · Disposition to issuer · Disposed 1,904 · Balance 0 F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option. F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.
F2: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.
F4: These Options are fully vested.
F5: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2021 Filed Jun 23, 2021 16:30 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantOption (right to buy) · Derivative | 8,500 | $0.00 Strike: $128.01 | $0.00 |
DisclosureSEC source: 0001593968-21-001682 · primary_01.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-06-15 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 17:51 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionOption (right to buy) · Derivative | 4,000 | $0.00 Strike: $84.86 | $0.00 |
DisclosureSEC source: 0001593968-21-001562 · primary_01.xml · derivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 4,000 shares Expires 2030-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020. Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 17:51 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | SaleCommon Stock | 4,000 | $112.93 | $451,720.00 |
DisclosureSEC source: 0001593968-21-001562 · primary_01.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 07, 2021 Filed Jun 7, 2021 17:51 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | Exercise / conversionCommon Stock | 4,000 | $84.86 | $339,440.00 |
DisclosureSEC source: 0001593968-21-001562 · primary_01.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 21:18 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (right to buy) · Derivative | 15,800 | $0.00 Strike: $77.79 | $0.00 |
DisclosureSEC source: 0001562180-21-003003 · primarydocument.xml · derivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,800 Underlying: Common Stock · 15,800 shares Expires 2031-04-27 F3 · derivative.exercise_date: The option vests as to one-third of the shares on April 27, 2022, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 21:18 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 4,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-003003 · primarydocument.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,540 F1 · shares: Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of shares on each of April 27, 2022, April 27, 2023 and April 27, 2024. F2 · balance_after: Includes 4,540 restricted stock units. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 16:26 UTC | Karuna Therapeutics, Inc. KRTX · Entity 92934 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $84.86 | $0.00 |
DisclosureSEC source: 0000899243-20-022412 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-08-11 F1 · derivative.exercise_date: This option shall vest and become exercisable in thirty-six equal monthly installments beginning on August 12, 2020. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 21:04 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 10,214 | $41.00 | $418,774.00 |
DisclosureSEC source: 0001225208-18-012551 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,672 Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 17:11 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 15,758 | $36.45 | $574,379.10 |
DisclosureSEC source: 0001225208-18-010376 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,886 Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 17:11 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 3,242 | $36.46 | $118,203.32 |
DisclosureSEC source: 0001225208-18-010376 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,644 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:02 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 38,546 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001225208-18-005112 · doc4.xml · derivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,546 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:02 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 23,397 | $35.70 | $835,272.90 |
DisclosureSEC source: 0001225208-18-005112 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,886 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:02 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 7,419 | $36.31 | $269,383.89 |
DisclosureSEC source: 0001225208-18-005112 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,283 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 21:02 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 38,546 | $27.37 | $1,055,004.02 |
DisclosureSEC source: 0001225208-18-005112 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:11 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 7,249 | $37.09 | $268,865.41 |
DisclosureSEC source: 0001225208-18-004669 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,156 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 23:11 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 19,847 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-004669 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,405 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:53 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 15,716 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004475 · doc4.xml · derivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,716 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:53 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 5,015 | $35.98 | $180,439.70 |
DisclosureSEC source: 0001225208-18-004475 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,558 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:53 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 3,649 | $36.26 | $132,312.74 |
DisclosureSEC source: 0001225208-18-004475 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,573 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:53 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 15,716 | $18.90 | $297,032.40 |
DisclosureSEC source: 0001225208-18-004475 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 25,064 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003978 · doc4.xml · derivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,064 Underlying: Common Stock · 25,064 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 29,981 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003978 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,981 Underlying: Common Stock · 29,981 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 19:51 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 8,064 | $32.70 | $263,692.80 |
DisclosureSEC source: 0001225208-17-014287 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,506 Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 2,667 | $34.28 | $91,424.76 |
DisclosureSEC source: 0001225208-17-005109 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,569 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 2,638 | $34.28 | $90,430.64 |
DisclosureSEC source: 0001225208-17-005109 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,236 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:10 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 7,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-005109 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,874 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 27,965 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · derivative · entry 7 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,965 Underlying: Common Stock · 27,965 shares Expires 2024-02-23 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 33,685 | $0.00 Strike: $34.06 | $0.00 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · derivative · entry 6 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,685 Underlying: Common Stock · 33,685 shares Expires 2022-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 27,306 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · derivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,306 shares Expires 2017-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 13,220 | $32.49 | $429,517.80 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,741 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 5,263 | $34.06 | $179,257.78 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,961 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:47 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 27,306 | $21.03 | $574,245.18 |
DisclosureSEC source: 0001225208-17-004781 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| May 11, 2016 Filed May 12, 2016 12:21 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 4,700 | $33.50 | $157,450.00 |
DisclosureSEC source: 0001225208-16-033182 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,659 Read SEC document |
| February 28, 2016 Filed Mar 2, 2016 00:13 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 2,670 | $30.23 | $80,714.10 |
DisclosureSEC source: 0001225208-16-028812 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,359 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 28, 2016 Filed Mar 2, 2016 00:13 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 1,333 | $30.23 | $40,296.59 |
DisclosureSEC source: 0001225208-16-028812 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,029 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 28, 2016 Filed Mar 2, 2016 00:13 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-16-028812 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,362 F1 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 25, 2016 Filed Feb 26, 2016 20:05 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 31,972 | $0.00 Strike: $30.59 | $0.00 |
DisclosureSEC source: 0001225208-16-028384 · doc4.xml · derivative · entry 7 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,972 Underlying: Common Stock · 31,972 shares Expires 2023-02-25 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 25, 2016 Filed Feb 26, 2016 20:05 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 35,776 | $0.00 Strike: $30.59 | $0.00 |
DisclosureSEC source: 0001225208-16-028384 · doc4.xml · derivative · entry 6 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,776 Underlying: Common Stock · 35,776 shares Expires 2021-02-25 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2016 Filed Feb 26, 2016 20:05 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionStock Appreciation Rights · Derivative | 18,984 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-16-028384 · doc4.xml · derivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,984 shares Expires 2016-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2016 Filed Feb 26, 2016 20:05 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 8,958 | $29.67 | $265,783.86 |
DisclosureSEC source: 0001225208-16-028384 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,759 F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2016 Filed Feb 26, 2016 20:05 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 3,750 | $30.02 | $112,575.00 |
DisclosureSEC source: 0001225208-16-028384 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,717 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. Read SEC document |
| February 24, 2016 Filed Feb 26, 2016 20:05 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 18,984 | $18.90 | $358,797.60 |
DisclosureSEC source: 0001225208-16-028384 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| June 11, 2015 Filed Jun 12, 2015 13:26 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $25.87 | $0.00 |
DisclosureSEC source: 0001225208-15-013736 · doc4.xml · derivative · entry 9 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,000 shares Expires 2017-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options are fully exercisable. Read SEC document |
| June 11, 2015 Filed Jun 12, 2015 13:26 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 12,100 | $34.40 | $416,240.00 |
DisclosureSEC source: 0001225208-15-013736 · doc4.xml · nonDerivative · entry 7 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,113 Read SEC document |
| June 11, 2015 Filed Jun 12, 2015 13:26 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 6,900 | $34.38 | $237,222.00 |
DisclosureSEC source: 0001225208-15-013736 · doc4.xml · nonDerivative · entry 6 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,213 Read SEC document |
| June 11, 2015 Filed Jun 12, 2015 13:26 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 5,500 | $34.39 | $189,145.00 |
DisclosureSEC source: 0001225208-15-013736 · doc4.xml · nonDerivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,113 Read SEC document |
| June 11, 2015 Filed Jun 12, 2015 13:26 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 900 | $34.37 | $30,933.00 |
DisclosureSEC source: 0001225208-15-013736 · doc4.xml · nonDerivative · entry 4 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,613 Read SEC document |
| June 11, 2015 Filed Jun 12, 2015 13:26 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 500 | $34.36 | $17,180.00 |
DisclosureSEC source: 0001225208-15-013736 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,513 Read SEC document |
| June 11, 2015 Filed Jun 12, 2015 13:26 UTC | PFIZER INC PFE · Entity 2863 | SaleCommon Stock | 100 | $34.35 | $3,435.00 |
DisclosureSEC source: 0001225208-15-013736 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,013 Read SEC document |
| June 11, 2015 Filed Jun 12, 2015 13:26 UTC | PFIZER INC PFE · Entity 2863 | Exercise / conversionCommon Stock | 26,000 | $25.87 | $672,620.00 |
DisclosureSEC source: 0001225208-15-013736 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.